L&T-TECHNOLOGY-SERVICES
16.9.2020 09:32:21 CEST | Business Wire | Press release
Exponential-e, a UK-based leading & innovative CSP of enterprise connectivity & unified communications services, today entered into a strategic partnership with L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, to jointly offer workplace transformation solutions to customers working in the post-COVID environment.
In the “new normal” brought on by the pandemic, enterprises are ramping up operations in phases and planning to bring back their workforce, with their health and safety being the top priority. During these times, the need of the hour for companies is to retrofit the workplace with safety solutions on a fully digital foundation that can scale to intelligent buildings/campuses, smart facilities and offices.
According to the partnership, LTTS will offer its latest solution i-BEMS™ Shield , built on the company’s award-winning i-BEMS™ framework, and anchored on Exponential-e’s next-gen composite SDN carrier grade network & cloud infrastructure. The combination of these solutions will accelerate digital transformation of the workplace, across industries through digital technologies and platforms.
LTTS’ Intelligent Building Experience Management System, i-BEMS™ is a modular ‘system-of-systems’ platform that unifies all campus operations under one system and focuses on creating digital experiences and building optimization.
To build future-facing workplaces, i-BEMS™ is deploying Shield , a module within the solution that automates and develops smart systems and provides real-time insights to diagnose inefficiencies for quick decision making. i-BEMS™ Shield’s advanced digital interface redefines contactless interaction and surveillance by enabling temperature detection, face detection and tracking, air quality management, occupancy management and energy management.
Exponential-e, a leader in delivering fast, low latency connectivity, flexible and resilient Cloud solutions and world class IT services, will provide the platform for i-BEMS™ Shield to scale new heights of safety at workspace. The company’s ‘Software Defined-Digital Platform’, anchored on world class SD-WAN hosting the LTTS full stack digital innovation applications has the potential to spawn an ecosystem powered by digital VAS; drones-as-a service, connected cars, video-analytics as a service, AR/VR, gaming, smart cities & intelligent buildings are high in impact & value. Every industry is transforming itself through mobility & digital technologies. The LTTS-Exponential-e partnership accelerates the transformation by enabling a platform-based business federated in structure for companies across industries to collaborate and co-create new markets and revenue generating services.
Lee Wade, Founder & CEO, Exponential-e said , “The needs of businesses in the post-COVID environment is set for a dramatic change. While green quotient and sustainability were focus areas earlier for adopting smart building frameworks for campuses, enterprises now are faced with the urgent need of ensuring a safe and secured workplace environment for their workforces. With increasing customer engagement devices being used to help the modern-day work environment, we provide a software-defined network where functions can be deployed seamlessly. We are pleased to partner with an engineering services leader like LTTS and are confident that together, we will co-develop a value proposition that aligns with the present day needs of businesses in this ‘new normal’ world.”
Gaurav Gupta, Chief Business Officer, Europe, at L&T Technology Services said , “Worldwide the most evident trend to emerge as a fallout of COVID-19 are the disruptive innovations driven by new-age digital technologies. The role of ER&D services in shaping such cutting-edge innovative solutions will only grow. Our strategic partnership with Exponential-e is one such initiative that promises to redefine the smart building ecosystem and we are glad to be the pioneers on this front along with Exponential. This tie-up will lay the foundation for multiple industry leading initiatives on smart and secure workspaces and campuses in the near future.”
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a publicly listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 53 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 16,600 employees spread across 17 global design centers, 28 global sales offices and 51 innovation labs as of June 30, 2020. For more information, visit https://www.ltts.com/
About Exponential‐e
Exponential-e is a Cloud, Connectivity and Communications pioneer with a difference. From launching the world’s first Virtual private LAN in 2006 on its privately-owned 100GigE secure and super-fast Network, to its recent launch of its Software-Defined Digital Platform (SD-DP). (https://www.exponential-e.com/solutions/digital-transformation-model ).
Exponential-e’s commitment to innovation has resulted in it being recognised as one of the fastest-growing private companies in the UK. Exponential-e has also built an extensive solutions portfolio, enabling the creation of services tailored specifically to its customers’ operational needs – whether that be for Private & Public Cloud, Data Centre, Unified Communications, Cyber Security or managed IT Services.
Delivering customer service excellence is at the heart of Exponential-e. That’s why it’s trusted by over 3,000 customers, with 96% reference-ability and an industry-leading Net Promoter Score of 73.
We work to international management standards and are accredited with 8 ISO accreditations. Today, Exponential-e employs 700 staff members across London, Manchester and Chippenham.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005140/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom